Across TCGA pan-cancer cohorts, OR4P4 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated OR4P4 data layer compared with 4 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher OR4P4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR4P4 expression acts as an unfavorable survival marker.
PDAC are the cancer types where OR4P4 mass-spec protein most reproducibly stratifies survival.